These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33567764)

  • 1. A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.
    Ishii H; Zahra MH; Takayanagi A; Seno M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cripto monoclonal antibodies.
    Hu XF; Xing PX
    Drug News Perspect; 2005 Jun; 18(5):293-303. PubMed ID: 16193101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
    Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
    J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of different Cripto-1 antibodies and their variable results.
    Gudbergsson JM; Duroux M
    J Cell Biochem; 2020 Jan; 121(1):545-556. PubMed ID: 31310365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro.
    Focà G; Iaccarino E; Focà A; Sanguigno L; Untiveros G; Cuevas-Nunez M; Strizzi L; Leonardi A; Ruvo M; Sandomenico A
    Biochimie; 2019 Mar; 158():246-256. PubMed ID: 30703478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.
    Normanno N; Tortora G; De Luca A; Pomatico G; Casamassimi A; Agrawal S; Mendelsohn J; Bianco AR; Ciardiello F
    Oncol Rep; 1999; 6(5):1105-9. PubMed ID: 10425310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cripto as a target for cancer immunotherapy.
    Hu XF; Xing PX
    Expert Opin Ther Targets; 2005 Apr; 9(2):383-94. PubMed ID: 15934922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers.
    Sandomenico A; Ruvo M
    Curr Med Chem; 2019; 26(11):1994-2050. PubMed ID: 30207211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line.
    Baldassarre G; Bianco C; Tortora G; Ruggiero A; Moasser M; Dmitrovsky E; Bianco AR; Ciardiello F
    Int J Cancer; 1996 May; 66(4):538-43. PubMed ID: 8635871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cripto: a novel target for antibody-based cancer immunotherapy.
    Xing PX; Hu XF; Pietersz GA; Hosick HL; McKenzie IF
    Cancer Res; 2004 Jun; 64(11):4018-23. PubMed ID: 15173016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the embryonic gene Cripto-1 in cancer and beyond.
    Bianco C; Salomon DS
    Expert Opin Ther Pat; 2010 Dec; 20(12):1739-49. PubMed ID: 21073352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
    Kelly RK; Olson DL; Sun Y; Wen D; Wortham KA; Antognetti G; Cheung AE; Orozco OE; Yang L; Bailly V; Sanicola M
    Eur J Cancer; 2011 Jul; 47(11):1736-46. PubMed ID: 21458984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues.
    Panico L; D'Antonio A; Salvatore G; Mezza E; Tortora G; De Laurentiis M; De Placido S; Giordano T; Merino M; Salomon DS; Mullick WJ; Pettinato G; Schnitt SJ; Bianco AR; Ciardiello F
    Int J Cancer; 1996 Jan; 65(1):51-6. PubMed ID: 8543395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant humanized Fab fragments targeting the CFC domain of human Cripto-1.
    Sandomenico A; Selis F; Sivaccumar JP; Olimpieri P; Iaccarino E; Cicatiello V; Cantile M; Sanna R; Leonardi A; De Falco S; Ruvo M
    Biochem Biophys Res Commun; 2024 Jan; 694():149417. PubMed ID: 38150919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exogenous Cripto-1 Suppresses Self-Renewal of Cancer Stem Cell Model.
    Alam MJ; Takahashi R; Afify SM; Oo AKK; Kumon K; Nawara HM; Khayrani AC; Du J; Zahra MH; Seno A; Salomon DS; Seno M
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma.
    Yoon HJ; Hong JS; Shin WJ; Lee YJ; Hong KO; Lee JI; Hong SP; Hong SD
    Oral Oncol; 2011 Nov; 47(11):1023-31. PubMed ID: 21824804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variants modulating CRIPTO serum levels identified by genome-wide association study in Cilento isolates.
    Ruggiero D; Nappo S; Nutile T; Sorice R; Talotta F; Giorgio E; Bellenguez C; Leutenegger AL; Liguori GL; Ciullo M
    PLoS Genet; 2015 Jan; 11(1):e1004976. PubMed ID: 25629528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF-κB/survivin signaling pathway.
    Zhang Y; Mi X; Song Z; Li Y; YingShi ; Niu J
    Biomed Pharmacother; 2018 Aug; 104():729-737. PubMed ID: 29807222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes.
    Marty C; Odermatt B; Schott H; Neri D; Ballmer-Hofer K; Klemenz R; Schwendener RA
    Br J Cancer; 2002 Jul; 87(1):106-12. PubMed ID: 12085265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, expression and characterization of a single chain anti-CD20 antibody; a germline humanized antibody derived from Rituximab.
    Ahmadzadeh V; Farajnia S; Hosseinpour Feizi MA; Khavarinejad RA
    Protein Expr Purif; 2014 Oct; 102():45-51. PubMed ID: 25088934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.